₹70 crore each in ophthalmology hospital chain Sharp Sight and Pune-based Murli Krishna Pharma Pvt. Ltd, a formulations maker that focuses on developing novel drug delivery system (NDDS) products Healthcare services and pharma focused private equity (PE) fund, India Life Sciences Fund III, made two investments worth ₹140 crore in the lockdown period.The PE firm invested ₹70 crore each in ophthalmology hospital chain Sharp Sight and Pune-based Murli Krishna Pharma Pvt.
Read more on livemint.com